scholarly journals Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant

2015 ◽  
Vol 4 (1) ◽  
pp. 51-58 ◽  
Author(s):  
Thomas Bertelmann ◽  
Stephan Schulze
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Fluocinolone Acetonide ◽  
Intravitreal Implant ◽  
Long Term Follow Up ◽  
Fluocinolone Acetonide Intravitreal Implant

Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results

2021 ◽  
pp. 112067212199298
Author(s):  
Argyrios Chronopoulos ◽  
Panagiotis Chronopoulos ◽  
Agharza Ashurov ◽  
Christina Korb ◽  
Norbert Pfeiffer ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Fluocinolone Acetonide ◽  
Additional Treatment ◽  
Multicentric Study ◽  
Goldmann Tonometry ◽  
Refractory Diabetic Macular Edema ◽  
Intravitreal Implant ◽  
Fluocinolone Acetonide Implant

Purpose: To report visual and anatomical outcomes of chronic/refractory diabetic macular edema (DME) treated with intravitreal fluocinolone acetonide implant. Setting: Retrospective, one arm, multicentric study. Method: Between 2013 and 2018, 27 consecutive eyes of 25 patients with chronic/refractory DME were treated with a fluocinolone acetonide intravitreal implant. Best registered visual acuity (BRVA), central retinal thickness (CRT), and Goldmann tonometry intraocular pressure (IOP) were assessed at 12 and 24 months. The need for IOP lowering treatment as well as top-up therapy during the follow-up were also assessed. Results: The duration of DME prior to treatment in our study was 54 ± 24 months. The baseline mean BRVA of 0.7 ± 0.34 logMAR improved to 0.5 ± 0.3 ( p = 0.01) at 12 months and 0.46 ± 0.3 ( p = 0.04) at 24 months. At 12 months, BRVA improved in 14 eyes (52%), stabilized in 5 eyes (20%), and decreased in 3 eyes (11%). At 24 months, BRVA improved further in 6 eyes (24%), stabilized in 3 eyes (12%), and decreased in 6 eyes (24 %). Mean CRT decreased from 497 ± 176 to 349 ± 186 μm at 12 months ( p = 0.0005) and to 267 ± 104 μm at 24 months ( p = 0.001). Only five eyes required additional treatment for DME and only three eyes required treatment for raised IOP. Discussion: Our results show that the visual and the anatomical improvements achieved by a single injection of a fluocinolone acetonide implant were maintained up to 24 months with minimal additional therapy even in eyes with a long and heavy history; however, IOP monitoring remains essential.

LONG-TERM FOLLOW-UP OF VITRECTOMY FOR DIFFUSE NONTRACTIONAL DIABETIC MACULAR EDEMA

Retina ◽  
2009 ◽  
Vol 29 (4) ◽  
pp. 464-472 ◽  
Author(s):  
KAZUYUKI KUMAGAI ◽  
MARIKO FURUKAWA ◽  
NOBUCHIKA OGINO ◽  
ERIC LARSON ◽  
MASAYOSHI IWAKI ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Long Term Follow Up

scholarly journals Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis

2021 ◽  
Vol 10 (17) ◽  
pp. 3966
Author(s):  
Muaas Hikal ◽  
Nil Celik ◽  
Gerd Uwe Auffarth ◽  
Lucy Joanne Kessler ◽  
Christian Steffen Mayer ◽  
...  
Keyword(s):  
Macular Edema ◽  
Fluocinolone Acetonide ◽  
Eye Drops ◽  
Intraretinal Fluid ◽  
Uveitic Macular Edema ◽  
Intravitreal Implant ◽  
Infectious Uveitis ◽  
Fluocinolone Acetonide Implant

The efficacy of the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema (UME) was assessed on twenty-six patients (34 eyes) with non-infectious UME between 2013 and 2020, in a mean follow-up of 18 ± 19.3 (mean ± SD) months. Macular edema was resolved in 24 (70.6%) cases. Five of these eyes had a relapse after 23.2 ± 14 months. Three FAc reinjections were performed and a drying of the macula was observed. After FAc implantation, 24 eyes (70.6%) were completely dry; central retinal thickness (CRT) decreased in 6 eyes (17.6%), but residual intraretinal fluid was still evident. In 20 eyes (58.5%), visual acuity (VA) improved (from +1 to +5 lines) and remained stable in 9 eyes (26.5%). Thirty eyes (88.2%) were pseudophakic at baseline and four were phakic. Three of these eyes had a cataract prior to therapy and the other developed a cataract 2.5 years after the FAc implant was administered. There was an overall increase in intraocular pressure (IOP; +4.4 ± 3.7 mmHg) and eye drops were required in three eyes. The FAc implant led to long-term improvements in mean CRT and VA, and that the side-effect profile was manageable in a clinical setting in patients with non-infectious UME.

Long-term follow-up of diabetic macular edema treated with dexamethasone implant: a real-life study

2020 ◽  
Vol 57 (12) ◽  
pp. 1413-1421 ◽  
Author(s):  
Thibaud Mathis ◽  
Théo Lereuil ◽  
Amro Abukashabah ◽  
Nicolas Voirin ◽  
Aditya Sudhalkar ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
Dexamethasone Implant ◽  
Life Study ◽  
Long Term Follow Up ◽  
Real Life Study
Sign in / Sign up

Export Citation Format

Share Document